Literature DB >> 8169777

Transdermal delivery of buprenorphine through cadaver skin.

S D Roy1, E Roos, K Sharma.   

Abstract

The skin permeation of buprenorphine base and HCl salt through cadaver skin was investigated. The octanol-water partition coefficient and solubilities of both buprenorphine free base and HCl salt were determined at 32 degrees C. As expected, buprenorphine free base was more lipophilic than its HCl salt and was practically insoluble in aqueous buffer at pH 8.7. The drug solubility decreased exponentially as the pH of the solution increased, whereas the permeability coefficient increased as the donor solution pH decreased. The skin flux of buprenorphine.HCl was significantly higher than that of the free base from propylene glycol/lauric acid vehicle mixtures. Buprenorphine base permeation through tape-stripped epidermis suggested that in addition to stratum corneum, viable epidermis presented a significant diffusion barrier because of the very low aqueous solubility of the free base observed. The mean steady-state skin fluxes of buprenorphine.HCl were 20.3 and 29.7 micrograms/cm2/h from propylene glycol:lauryl alcohol: ethanol (80:15:5) and propylene glycol: propylene glycol monolaurate: water (80:15:5) vehicle mixtures, respectively. The skin flux of buprenorphine.HCl from various monolithic matrix patches was also evaluated. When capric acid, lauric acid, and lauryl alcohol were separately incorporated into an adhesive matrix, the skin flux of buprenorphine.HCl was enhanced by a factor of 2 to 3.5. Finally, based on the total body clearance and minimum effective concentration of buprenorphine, a transdermal delivery rate of 2.5 micrograms/cm2/h from a 20-cm2 patch was estimated. The in vitro skin permeation data clearly suggest that transdermal delivery of buprenorphine is feasible to achieve a desired systemic analgesic effect.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8169777     DOI: 10.1002/jps.2600830204

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  Comparative pharmacokinetics of intravenous fentanyl and buprenorphine in healthy greyhound dogs.

Authors:  B KuKanich; P Allen
Journal:  J Vet Pharmacol Ther       Date:  2014-03-29       Impact factor: 1.786

2.  Permeation of buprenorphine and its 3-alkyl-ester prodrugs through human skin.

Authors:  A L Stinchcomb; A Paliwal; R Dua; H Imoto; R W Woodard; G L Flynn
Journal:  Pharm Res       Date:  1996-10       Impact factor: 4.200

Review 3.  Transdermal patches: history, development and pharmacology.

Authors:  Michael N Pastore; Yogeshvar N Kalia; Michael Horstmann; Michael S Roberts
Journal:  Br J Pharmacol       Date:  2015-03-18       Impact factor: 8.739

Review 4.  Probuphine® (buprenorphine implant): a promising candidate in opioid dependence.

Authors:  Preeti Barnwal; Saibal Das; Somnath Mondal; Anand Ramasamy; Tanay Maiti; Arunava Saha
Journal:  Ther Adv Psychopharmacol       Date:  2016-12-19

Review 5.  Buprenorphine in cancer pain.

Authors:  Mellar P Davis
Journal:  Support Care Cancer       Date:  2005-07-12       Impact factor: 3.603

6.  Novel microemulsion enhancer formulation for simultaneous transdermal delivery of hydrophilic and hydrophobic drugs.

Authors:  Philp J Lee; Robert Langer; V Prasad Shastri
Journal:  Pharm Res       Date:  2003-02       Impact factor: 4.200

7.  Prediction of aqueous intrinsic solubility of druglike molecules using Random Forest regression trained with Wiki-pS0 database.

Authors:  Alex Avdeef
Journal:  ADMET DMPK       Date:  2020-03-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.